Population and public health: Hepatitis B immunization strategies: Timing is everything

CMAJ. Canadian Medical Association Journal

Volumn 180, Issue 2, 2009, Pages 196-202

  Mackie, Christopher O ^a,b,e   Buxton, Jane A ^c,d   Tadwalkar, Sayali ^d   Patrick, David M ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b City of Hamilton   (Canada)

^c BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ARTICLE; HEPATITIS B; HUMAN; IMMUNITY; IMMUNIZATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; VACCINATION; ADOLESCENT; ADULT; CANADA; CHILD; HEALTH; INCIDENCE; INFANT; MASS IMMUNIZATION; PREVALENCE; REVIEW;

ADOLESCENT; ADULT; CANADA; CHILD; HEPATITIS B; HEPATITIS B, CHRONIC; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INCIDENCE; INFANT; MASS IMMUNIZATION; PREVALENCE; WORLD HEALTH;

EID: 58849115548     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.081112     Document Type: Article

References (47)

1. Gilca V, Duval B, Boulianne N, et al. Impact of the Quebec school-based hepatitis B immunization program and potential benefit of the addition of an infant immunization program. Pediatr Infect Dis J 2006;25:372-4.
2. English P. Should universal hepatitis B immunization be introduced in the UK? Arch Dis Child 2006;91:286-9.
3. Beasley RP, Hwang LY, Lin CC, et al. Incidence of hepatitis B virus infections in preschool children in Taiwan. J Infect Dis 1982;146:198-204.
4. McMahon BJ, Alward WL, Hall DB, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985;151:599-603.
5. Tassopoulos NC, Papaevangelou GJ, Sjogren MH, et al. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology 1987;92:1844-50.
6. Nguyen VT, Law MG, Dore GJ. An enormous hepatitis B virus-related liver disease burden projected in Vietnam by 2025. Liver Int 2008;28:525-31.
7. Shepard CW, Finelli L, Fiore AE, et al. Epidemiology of hepatitis B and hepatitis B virus infection in United States children. Pediatr Infect Dis J 2005;24:755-60.
8. Qamer S, Shahab T, Alam S, et al. Age-specific prevalence of hepatitis B surface antigen in pediatric population of Aligarh, North India. Indian J Pediatr 2004;71:965-7.
9. McMahon BJ, Schoenberg S, Bulkow L, et al. Seroprevalence of hepatitis B viral markers in 52,000 Alaska Natives. Am J Epidemiol 1993;138:544-9.
10. Whittle H, Jaffar S, Wansbrough M, et al. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ 2002;325:569.
11. Dentinger CM, McMahon BJ, Butler JC, et al. Persistence of antibody to hepatitis B and protection from disease among Alaska Natives immunized at birth. Pediatr Infect Dis J 2005;24:786-92.
12. Liao S-S, Li R-C, Li H, et al. Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children. Vaccine 1999;17:2661-6.
13. Yuen M-F, Lim W-L, Chan AO-O, et al. 18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children. Clin Gastroenterol Hepatol 2004;2:941-5.
14. van der Sande MA, Waight PA, Mendy M, et al. Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. PLoS ONE 2007;2:e753.
15. Expanded Programme on Immunization of the Department of Immunizations, Vaccines and Biologicals. WHO vaccine-preventable diseases: monitoring system, 2007 global summary. Geneva (Switzerland): World Health Organization; 2007. Available: http://whqlibdoc.who.int/hq/2007/WHO-IVB-2007-eng.pdf (accessed 2008 Dec 3).
16. Da Villa G, Peluso F, Picciotto L, et al. Persistence of anti-HBs in children vaccinated against viral hepatitis B in the first year of life: follow-up at 5 and 10 years. Vaccine 1996;14:1503-5.
17. Da Villa G, Pelliccia MG, Peluso F, et al. Anti-HBs responses in children vaccinated with different schedules of either plasma-derived or HBV DNA recombinant vaccine. Res Virol 1997;148:109-14.
18. Poovorawan Y, Theamboonlers A, Hirsch P, et al. Persistence of antibodies to the surface antigen of the hepatitis B virus (anti-HBs) in children subjected to the Expanded Programme on Immunization (EPI), including hepatitis-B vaccine, in Thailand. Ann Trop Med Parasitol 2000;94:615-21.
19. Su F-H, Chen J-D, Cheng S-H, et al. Waning-off effect of serum hepatitis B surface antibody amongst Taiwanese university students: 18 years post-implementation of Taiwan's national hepatitis B vaccination programme. J Viral Hepatitis 2008;15:4-9.
20. Schreeder MT, Bender TR, McMahon BJ, et al. Prevalence of hepatitis B in selected Alaskan Eskimo villages. Am J Epidemiol 1983;118:543-9.
21. Barrett DH, Burks JM, McMahon B, et al. Epidemiology of hepatitis B in two Alaskan communities. Am J Epidemiol 1977;105:118-22.
22. Sung JL, Chen DS, Lai MY et al. Epidemiological study on hepatitis B virus infection in Taiwan. Chin J Gastroenterol 1984;1:1-9.
23. Wu JS, Chen CH, Chiang YH, et al. Hepatitis B virus infection in Taiwan with reference to anti-HBc versus HBsAg and anti-HBs. Taiwan Yi Xue Hui Za Zhi 1980;79:760-7.
24. Lok AS, Lai CL, Wu PC, et al. Hepatitis B infection in Chinese families in Hong Kong. Am J Epidemiol 1987;126:492-9.
25. Coursaget P, Leboulleux D, Soumare M, et al. Twelve-year follow-up study of hepatitis B immunization of Senegalese infants. J Hepatol 1994;21:250-4.
26. Berlioz-Arthaud A, Perolat P, Buisson Y. 10 year assessment of infant hepatitis B vaccination program, in the Loyalty Islands (New Caledonia). Vaccine 2003;21:2737-42.
27. Tsatsralt-Od B, Takahashi M, Endo K, et al. Prevalence of hepatitis B, C, and Delta virus infections among children in mongolia: progress in childhood immunization. J Med Virol 2007;79:1064-74.
28. Edstam JS, Dulmaa N, Nymadawa P, et al. Comparison of hepatitis B vaccine coverage and effectiveness among urban and rural Mongolian 2-year-olds. Prev Med 2002;34:207-14.
29. Davaalkham D, Ojima T, Wiersma S, et al. Administration of hepatitis B vaccine in winter as a significant predictor of the poor effectiveness of vaccination in rural Mongolia: evidence from a nationwide survey. J Epidemiol Community Health 2007;61:578-84.
30. The World Health Organization. Progress towards global immunization goals - 2007: summary presentation of key indicators. Geneva: The Organization; 2008. Available: www.who.int/immunization-monitoring/data/SlidesGlobalImmunization. pdf (accessed 2008 Dec 3).
31. Public Health Agency of Canada. Publicly funded immunization programs in canada: routine schedule for infants and children (including special programs and catch-up programs). Ottawa (ON): The Agency; 2007. Available: www.phac-aspc.gc.ca/im/ptimprog-progimpt/table-1-eng.php (accessed 2008 Dec 15).
32. Patrick DM, Bigham M, Ng H, et al. Elimination of acute hepatitis B among adolescents after one decade of an immunization program targeting Grade 6 students. Pediatr Infect Dis J 2003;22:874-7.
33. Salleras L, Dominguez A, Bruguera M, et al. Dramatic decline in acute hepatitis B infection and disease incidence rates among adolescents and young people after 12 years of a mass hepatitis B vaccination programme of pre-adolescents in the schools of Catalonia (Spain). Vaccine 2005;23:2181-4.
34. BC Centre for Disease Control. 2007 British Columbia Annual Summary of Reportable Diseases. Vancouver (BC): The Centre; 2008, Available: www.bccdc.org/content.php?item=33 (accessed 2008 Dec 3).
35. Notifiable diseases online. Ottawa (ON): Centre for Infectious Disease Prevention and Control, Public Health Agency of Canada; 2004. Available: http://dsol-smed.phac-aspc.gc.ca/dsol-smed/ndis/m-ind-e.html#maps (accessed 2008 Dec 3).
36. Rapport sur l'ensemble des maladies des dix dernières années, Province du Quebec. Québec (QC): Institut national de sante publique du Quebec; 2008. Available: www.dspq.qc.ca/MADO/asp/ rapportPublic.asp?id=0# (accessed 2008 Sept 18).
37. BC Stats. Immigration by Area of Last Permanent Residence, January to December, 2006. British Columbia: BC Stats; 2007. Available: www.bcstats.gov.bc.ca/DATA/pop/mig/imm06t1a.pdf (accessed 2008 Dec 10).
38. Lee C, Gong Y, Brok J, et al. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ 2006;332:328-36.
39. Statistics Canada. Births and birth rate, by province and territory. Ottawa (ON): Statistics Canada; 2008. Available: www40.statcan.gc.ca/l01/cst01/ demo04a-eng.htm (accessed 2008 August 15).
40. West DJ, Calandra GB. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 1996;14:1019-27.
41. European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 2000;355:561-5.
42. FitzSimons D, François G, Hall A, et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine 2005;23:4158-66.
43. Van Damme P, Van Herck K. A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis 2007;5:79-84.
44. Erickson LJ, De Wals P, Farand L. An analytical framework for immunization programs in Canada. Vaccine 2005;23:2470-6.
45. Lu C-Y, Ni Y-H, Chiang B-L, et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. J Infect Dis 2008;197:1419-26.
46. Center for Disease Control and Prevention (CDC). Vaccines and immunizations, programs and tools: CDC vaccine price list [prices last reviewed/updated: 2008 Nov 5]. Atlanta (GA): Centers for Disease Control and Prevention; 2008. Available: www.cdc.gov/vaccines/programs/vfc/cdc-vac-price- list.htm (accessed 2008 Nov 18).
47. Scheifele D. Universal childhood hepatitis B vaccination: infants vs. preadolescents, the Canadian perspective. Pediatr Infect Dis J 1998;17:S35-7.